Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax + zanubrutinib versus venetoclax + acalabrutinib in previously untreated chronic lymphocytic leukemia
NL-OMON61058Phase 3Recruiting
- Sponsor
- BeOne Medicines
- Start
- Jun 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sonrotoclax, zanubrutinib, venetoclax and acalabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by BeOne Medicines. Primary endpoint: Progression-free survival. Started Jun 2026; status: recruiting.
02
Drugs
sonrotoclaxzanubrutinibvenetoclaxacalabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON61058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61058.